Please select the option that best describes you:

In patients with stage II-III HER2+ breast cancer who were not treated with neoadjuvant therapy, without having knowledge of response to neoadjuvant therapy (i.e. pCR or not) after chemotherapy, what is your preferred adjuvant HER2 directed therapy?  

Which patients should receive TDM-1, Trastuzumab+Pertuzumab or Trastuzumab alone?



Answer from: Medical Oncologist at Academic Institution

Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at NYU Winthrop Hospital
Katherine trial has changed my use of Adjuvant th...
Sign in or Register to read more